Cwm LLC Increases Stake in Tenet Healthcare Corporation $THC

Cwm LLC grew its stake in Tenet Healthcare Corporation (NYSE:THC) by 150.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 45,483 shares of the company’s stock after purchasing an additional 27,320 shares during the period. Cwm LLC’s holdings in Tenet Healthcare were worth $9,235,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Chung Wu Investment Group LLC acquired a new stake in Tenet Healthcare during the second quarter valued at $35,000. Canada Pension Plan Investment Board acquired a new stake in shares of Tenet Healthcare during the 2nd quarter valued at about $35,000. Trust Co. of Vermont acquired a new position in Tenet Healthcare in the 3rd quarter worth about $41,000. Caitong International Asset Management Co. Ltd boosted its position in Tenet Healthcare by 2,227.3% during the second quarter. Caitong International Asset Management Co. Ltd now owns 256 shares of the company’s stock worth $45,000 after purchasing an additional 245 shares in the last quarter. Finally, True Wealth Design LLC grew its holdings in Tenet Healthcare by 238.2% in the second quarter. True Wealth Design LLC now owns 257 shares of the company’s stock valued at $45,000 after purchasing an additional 181 shares during the period. 95.44% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Nadja West sold 2,178 shares of Tenet Healthcare stock in a transaction on Monday, December 15th. The stock was sold at an average price of $197.47, for a total transaction of $430,089.66. Following the transaction, the director owned 28,480 shares in the company, valued at $5,623,945.60. The trade was a 7.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Tammy Romo sold 645 shares of the firm’s stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $205.20, for a total transaction of $132,354.00. Following the sale, the director owned 34,866 shares of the company’s stock, valued at approximately $7,154,503.20. The trade was a 1.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 45,500 shares of company stock valued at $9,247,071 over the last 90 days. Insiders own 0.81% of the company’s stock.

Tenet Healthcare Stock Up 0.2%

THC stock opened at $200.97 on Tuesday. The company has a current ratio of 1.71, a quick ratio of 1.64 and a debt-to-equity ratio of 2.27. The firm has a 50-day moving average of $203.21 and a two-hundred day moving average of $187.89. Tenet Healthcare Corporation has a 12 month low of $109.82 and a 12 month high of $222.82. The company has a market cap of $17.66 billion, a price-to-earnings ratio of 13.77, a PEG ratio of 0.88 and a beta of 1.44.

Tenet Healthcare (NYSE:THC) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $3.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.33 by $0.37. Tenet Healthcare had a return on equity of 25.11% and a net margin of 6.49%.The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.26 billion. During the same period in the prior year, the business earned $2.93 earnings per share. The business’s revenue was up 3.2% compared to the same quarter last year. Tenet Healthcare has set its FY 2025 guidance at 15.930-16.26 EPS. As a group, analysts forecast that Tenet Healthcare Corporation will post 12.24 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on THC. Morgan Stanley reiterated an “overweight” rating and set a $247.00 target price on shares of Tenet Healthcare in a research report on Thursday, December 18th. Cantor Fitzgerald upped their price objective on shares of Tenet Healthcare from $190.00 to $245.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Weiss Ratings reissued a “hold (c+)” rating on shares of Tenet Healthcare in a research note on Monday, December 22nd. Bank of America upped their price target on shares of Tenet Healthcare from $205.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, September 10th. Finally, Wells Fargo & Company lifted their price objective on Tenet Healthcare from $238.00 to $252.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $231.81.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.